GRAL GRAIL, LLC
Company Analysis
Latest News
🟢 GRAIL rises 5.3% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
GRAIL Faces Misconduct Probe, Following Failed NHS-Galleri Cancer Trial
A law firm is investigating GRAIL, Inc. officers and directors for potential wrongdoing on behalf of long-term investors. This probe follows a lawsuit alleging...
🟢 GRAIL is trading 5% up today
GRAIL is trading 5.3% up at $77.88, with no clear company-specific catalyst identified for August 20, 2026. - The latest material development is the FDA’s...
🟢 GRAIL is trading 4.8% up today as immediate catalyst remains unclear
GRAIL is trading 4.8% up at $77.48, while the immediate catalyst remains unclear. - No new company-specific announcement dated August 20, 2026, was identified...
🟢 GRAIL is trading 6.2% up today amid biotech rally after positive Moderna cancer-vaccine results
GRAIL is trading 6.2% up at $75.30, significantly outperforming its August 18 close of $70.89 amid biotech-sector strength following positive Moderna...
🟢 GRAIL is trading 4.2% up today amid optimism over FDA’s September 23 Galleri review
GRAIL is trading at $70.73, up 4.21%, as investors focus on the FDA’s scheduled September 23 advisory committee review of Galleri’s premarket approval...
🔴 GRAIL is trading 4% down today after three advancing sessions
GRAIL is trading 4.01% down now at $72.45, reversing after three consecutive advancing sessions; no reliable source identifies a new company-specific...
GRAIL's Revenue Beat Couldn't Mask a Pricing Problem — Can the Cancer-Detection Pioneer Grow Without Giving Away the Store?
Shares of GRAIL plunged 8.3% to $68.00 in after-hours trading following a second-quarter report that, on the surface, looked strong — revenue of $44.7 million...
🟢 GRAIL is trading 5% up today after FDA plans September Galleri advisory meeting
GRAIL is trading 5.47% up now at $66.87 after the FDA announced plans for a September advisory committee meeting on Galleri, its multi-cancer screening...
🔴 GRAIL is trading 11.37% down today after adjusted EBITDA losses widened
GRAIL is trading 11.37% down now at $65.75 after investors reacted negatively to its August 5 earnings and wider adjusted EBITDA losses. - Revenue reached...
🔴 GRAIL is trading 8.67% down today after adjusted EBITDA losses widened
GRAIL is trading 8.67% down now at $67.75 after investors focused on widening adjusted EBITDA losses following its August 5, 2026 earnings release. -...
🔴 GRAIL is trading 5.5% down today as initial earnings gains reverse on pricing pressure concerns
GRAIL is trading at $70.12 (-5.47%) in pre-market as the initial positive reaction to its Q2 earnings report reversed due to concerns over monetization. • The...
🔴 GRAIL is trading 8.3% down today on weak commercial mix and guidance tone
GRAIL is trading at $68.00 (-8.33%) following its second-quarter update, as investors focus on a weaker-than-expected commercial mix and cautious guidance...
GRAIL, LLC Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect GRAIL to report a consensus revenue of $42.39 million and a loss per share of $2.66, with the stock currently...
🟢 GRAIL is trading 4.1% up today amid a broader market rebound and risk-on sentiment
GRAIL is trading at $71.34 (4.1% up), rebounding from last week’s biotech volatility and Friday’s sector-wide selloff. • The advance aligns with a broader...
🔴 GRAIL is trading 4.7% down today amid a broader biotech selloff and reversal of yesterday's rally
GRAIL is trading 4.7% down at $67.77 today, reversing a portion of yesterday's gains as the broader biotech sector faces selling pressure. • The decline...
🟢 GRAIL is trading 10.6% up today amid tech rebound and cooling inflation
GRAIL is trading 10.6% up now at $70.19 amid a strong rebound in technology stocks driven by cooling inflation data and robust Microsoft earnings. • Broader...
🟢 GRAIL is trading 7.7% up today amid a broader tech rebound and cooling inflation
GRAIL is trading 7.7% up now at $68.33 as part of a broader rebound in technology shares driven by cooling inflation and strong Microsoft earnings. • The...
🔴 GRAIL falls 4.2% — Biotech Stocks Decline on Broad Market Weakness
With Biotech (XBI) down 2.2%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 GRAIL is trading 4.1% down today amid broader biotech caution and tariff uncertainty
GRAIL is trading 4.1% down at $67.50 today, appearing to move in line with cautious sentiment toward high-cost biotech and diagnostics plays rather than a...